Want to see SE:CLBIO full AI Analyst Report?
Top Page
Corline Biomedical AB
(CLBIO)
Select Model
Select Model
Rating:49Neutral
Price Target:
kr16.50
▼(-6.25% Downside)
Action:Reiterated
Date:08/27/26
The score is primarily held back by weak financial performance (ongoing losses and cash burn) despite a strong, low-risk balance sheet with zero debt. Technicals also lean bearish with the stock trading below major moving averages and subdued momentum. Valuation provides limited support due to a negative P/E and no dividend yield data.
Positive Factors
Revenue Growth
Strong TTM revenue growth indicates increasing customer adoption of Corline’s blood-compatible technologies. Sustained commercial traction could support operating leverage and improve the path toward profitability if growth converts into higher-margin recurring sales.
Negative Factors
Persistent Net Losses
Persistent losses show that commercial growth has not yet translated into a self-sustaining earnings model. Continued negative margins could constrain reinvestment capacity and increase dependence on future financing unless scale and gross economics improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Strong TTM revenue growth indicates increasing customer adoption of Corline’s blood-compatible technologies. Sustained commercial traction could support operating leverage and improve the path toward profitability if growth converts into higher-margin recurring sales.
Read all positive factors
Corline Biomedical AB (CLBIO) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr492.61M
Dividend YieldN/A
Average Volume (3M)90.01K
Price to Earnings (P/E)―
Beta (1Y)0.31
Revenue Growth54.37%
EPS Growth52.22%
CountrySE
Employees13
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.49
Shares Outstanding26,133,118
10 Day Avg. Volume161,073
30 Day Avg. Volume90,008
Financial Highlights & Ratios
PEG Ratio0.63
Price to Book (P/B)4.33
Price to Sales (P/S)53.02
P/FCF Ratio-22.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.7
Revenue Forecast (FY)kr41.80M
Corline Biomedical AB Business Overview & Revenue Model
Company Description
Corline Biomedical AB is a company dedicated to the creation, production, and distribution of heparin-based solutions. These solutions are specifically engineered to enhance outcomes in kidney transplantation, cellular therapies, and regenerative ...
How the Company Makes Money
Corline Biomedical makes money primarily by commercializing its blood-compatible biomaterial and surface-technology solutions through product sales and B2B collaborations. Key revenue streams typically include: (1) Sales of proprietary products/co...
Corline Biomedical AB Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
74
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.39M | 7.65M | 9.78M | 25.03M | 23.55M | 7.06M |
| Gross Profit | -1.17M | -14.21M | 13.44M | 28.38M | 22.73M | 9.10M |
| EBITDA | -12.23M | -14.12M | -23.07M | -1.69M | 2.38M | -6.88M |
| Net Income | -12.32M | -14.71M | -23.19M | -1.81M | 2.33M | -6.92M |
Balance Sheet | ||||||
| Total Assets | 114.18M | 98.58M | 94.76M | 100.11M | 101.78M | 101.66M |
| Cash, Cash Equivalents and Short-Term Investments | 32.99M | 20.56M | 17.67M | 17.01M | 26.21M | 41.63M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 15.18M | 4.82M | 7.85M | 6.79M | 7.19M | 9.43M |
| Stockholders Equity | 99.00M | 93.76M | 86.91M | 93.32M | 94.59M | 92.23M |
Cash Flow | ||||||
| Free Cash Flow | -14.83M | -17.74M | -16.14M | -9.73M | -15.45M | -14.45M |
| Operating Cash Flow | -14.44M | -17.69M | -8.64M | 886.00K | -6.45M | -4.83M |
| Investing Cash Flow | -750.00K | -982.00K | -7.50M | -10.62M | -9.00M | -9.56M |
| Financing Cash Flow | 39.87M | 21.56M | 16.79M | 537.00K | 26.00K | 47.13M |
Corline Biomedical AB Technical Analysis
Negative
17.60
Price Trends
17.78
Negative
17.45
Negative
17.21
Negative
Market Momentum
0.04
Positive
38.00
Neutral
54.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLBIO, the sentiment is Negative. The current price of 17.6 is below the 20-day moving average (MA) of 17.90, below the 50-day MA of 17.78, and above the 200-day MA of 17.21, indicating a bearish trend. The MACD of 0.04 indicates Positive momentum. The RSI at 38.00 is Neutral, neither overbought nor oversold. The STOCH value of 54.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CLBIO.
Corline Biomedical AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | kr4.41B | -5.48 | ― | ― | -3.57% | 8.84% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | kr492.61M | -29.07 | ― | ― | 54.37% | 52.22% | |
48 Neutral | kr141.05M | -2.47 | -80.87% | ― | 7.80% | 42.81% | |
48 Neutral | kr91.81M | -2.43 | -120.70% | ― | -97.37% | 25.28% | |
41 Neutral | kr546.07M | -6.97 | ― | ― | ― | -23.57% |
* General Sector Average
SE:CLBIO
Corline Biomedical AB
16.35
3.40
26.25%
SE:HNSA
Hansa Biopharma AB
44.18
12.26
38.41%
SE:NXTCL
NextCell Pharma AB
1.05
-0.13
-10.88%
SE:SPAGO
Spago Nanomedical AB
0.11
-0.07
-37.29%
SE:BIOWKS
Bio-Works Technologies AB
3.26
0.10
3.16%
SE:FLUO
FluoGuide A/S
33.50
-7.40
-18.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.